NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

Начало・Списък с акции・Genmab A-S

Genmab A-S

Затворен

1,621 0.06

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1606

Максимум

1628

Ключови измерители
By Trading Economics
Приходи	21M 52M
Продажби	-184M 881M
P/E Средно за сектора	18.691 49.052
EPS	8.48
Марж на печалбата	5.915
Служители	3,088
EBITDA	-23M 221M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-1.49% downside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-7.6B 97B
Предишно отваряне	1620.94
Предишно затваряне	1621

Genmab A-S Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.06.2026 г., 23:56 ч. UTC

Event

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

11.06.2026 г., 23:56 ч. UTC

Correlated Moves

ETF Constituents

Macro News

iShares MSCI Brazil ETF trades higher after President Trump's cancellation of military strikes against Iran, boosting global investor confidence.

11.06.2026 г., 23:56 ч. UTC

News

Monster Beverage shares higher in after-market trading following Bernstein's initiation of coverage with a Market Perform rating. The stock has gained over four consecutive sessions.

11.06.2026 г., 23:52 ч. UTC

Michigan Consumer Sentiment Report for June 2026 Forecasts Continued Decline at 46.0 Amid Economic Pressures and Inflation Concerns

11.06.2026 г., 23:52 ч. UTC

Investors Await Key U.S. Building Permits Report Amid Cautious Market Sentiment Ahead of June 16 Release

11.06.2026 г., 23:52 ч. UTC

Macro Event

News

Correlated Moves

The Australian Dollar has gained against the Singapore Dollar, supported by a slight decline in consumer inflation expectations and recent geopolitical developments.

11.06.2026 г., 23:51 ч. UTC

News

The iShares Core U.S. Aggregate Bond ETF is trading lower in after-market hours, reflecting concerns over inflation following a rise in the producer price index.

11.06.2026 г., 23:51 ч. UTC

Correlated Moves

Lam Research Corp is rising in after-market trading, supported by a broader market rally and strong momentum near the upper end of its one-month trading range.

11.06.2026 г., 23:51 ч. UTC

Correlated Moves

Costco Wholesale Corp shares are higher in after-market hours, supported by a rising Nasdaq 100 Index and positive sentiment in the consumer staples sector.

11.06.2026 г., 23:51 ч. UTC

Trip.com Group Ltd is higher in after-market hours, reflecting broader market gains. No specific company news was identified to explain this movement.

11.06.2026 г., 23:51 ч. UTC

ETF Constituents

Vanguard FTSE Europe ETF is trading lower in after-market hours, impacted by declines from holdings including HSBC and Diageo, despite a generally higher market.

11.06.2026 г., 23:51 ч. UTC

Marriott International Inc. shares declined in after-market hours following Thursday's close, with no specific news identified to explain the movement.

11.06.2026 г., 23:51 ч. UTC

PepsiCo Inc shares are higher in after-market hours, driven by a significant overall market trend. The stock remains below its 20-day moving average.

11.06.2026 г., 23:51 ч. UTC

Lululemon Athletica is trading lower in after-market hours, reflecting a decline since Thursday's close. It reached a session low earlier in the session.

11.06.2026 г., 23:51 ч. UTC

Correlated Moves

ETF Constituents

News

Social Media

SPDR S&P 500 ETF Trust rises in after-hours trading amid improved market sentiment and reduced geopolitical tensions in Iran, supported by strong performances from top holdings.

11.06.2026 г., 23:51 ч. UTC

Correlated Moves

ETF Constituents

News

Social Media

Invesco QQQ Trust Series I rises after hours, supported by a Nasdaq 100 rally driven by technology stocks and easing inflation concerns.

11.06.2026 г., 23:51 ч. UTC

ETF Constituents

Correlated Moves

Macro News

Global X Copper Miners ETF declines in after-market trading as top holdings BHP and Southern Copper Corporation show slight decreases.

11.06.2026 г., 23:51 ч. UTC

Correlated Moves

Microchip Technology Inc is rising in after-market trading, reflecting broader market trends amid the European Central Bank's recent interest rate hike.

11.06.2026 г., 23:51 ч. UTC

Social Media

Correlated Moves

Micron Technology is trading higher in after-market hours, supported by positive market trends and favorable social media sentiment ahead of upcoming earnings.

11.06.2026 г., 23:51 ч. UTC

Correlated Moves

The Nasdaq 100 Index is higher today, continuing its upward trend. Initial jobless claims rose unexpectedly, but this has not impacted the index's momentum.

11.06.2026 г., 23:51 ч. UTC

News

The United States Oil Fund LP is higher in after-market trading amid reports of explosions in Iran raising concerns over oil supply stability.

11.06.2026 г., 23:46 ч. UTC

Intuitive Surgical Inc. shares are higher in after-market trading, advancing modestly since Thursday's close despite remaining below the 20-day moving average.

11.06.2026 г., 23:46 ч. UTC

Oil (Brent) is trading roughly flat with no specific news identified. It remains 7.63% below its 20-day moving average, indicating weak performance.

11.06.2026 г., 23:46 ч. UTC

ETF Constituents

Correlated Moves

The Vanguard FTSE Developed Markets ETF is trading higher in after-market hours, buoyed by the European Central Bank's interest rate hike and strong performances from SAP and BP.

11.06.2026 г., 23:42 ч. UTC

Housing Starts Data Release on June 16, 2026 Expected at 1.44 Million Amid Mixed Economic Sentiment and Inflation Concerns

11.06.2026 г., 23:42 ч. UTC

U.S. Import Prices Expected to Rise Amid Inflation Concerns and Geopolitical Tensions Ahead of June 16 Release

11.06.2026 г., 23:42 ч. UTC

U.S. Export Prices Expected to Rise 1% MoM Amid Mixed Economic Sentiment and Geopolitical Tensions Ahead of June 16 Release

11.06.2026 г., 23:42 ч. UTC

Market Awaits May Housing Starts Data Amid Economic Uncertainties and Rising Costs.

11.06.2026 г., 23:42 ч. UTC

U.S. Building Permits Expected to Rise Slightly to 1.41 Million Amid Cautious Optimism Ahead of June Release

11.06.2026 г., 23:42 ч. UTC

Macro News

ETF Constituents

Investor sentiment towards the Consumer Staples Select Sector SPDR Fund improves in after-market trading, buoyed by macro developments and strong performances from key holdings.

Сравнение с други в отрасъла

Ценова промяна

Genmab A-S Прогноза

Ценова цел

By TipRanks

-1.49% надолу

12-месечна прогноза

Среден 2,493.35 DKK -1.49%

Висок 3,320 DKK

Нисък 308.417 DKK

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Genmab A-S през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Genmab A-S през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.